High throughput screening for compounds to the orphan nuclear receptor NR2F6.
Cancer
High-throughput screening (HTS)
Immuno-oncology drug discovery
NR2F6
Nuclear receptor
Journal
SLAS discovery : advancing life sciences R & D
ISSN: 2472-5560
Titre abrégé: SLAS Discov
Pays: United States
ID NLM: 101697563
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
21
12
2021
revised:
08
03
2022
accepted:
18
03
2022
pubmed:
26
3
2022
medline:
9
6
2022
entrez:
25
3
2022
Statut:
ppublish
Résumé
NR2F6 is considered an orphan nuclear receptor since its endogenous ligand has yet to be identified. Recently, NR2F6 has emerged as a novel cancer therapeutic target. NR2F6 has been demonstrated to be upregulated or overexpressed in several cancers. Importantly, Nr2f6
Identifiants
pubmed: 35331960
pii: S2472-5552(22)12551-7
doi: 10.1016/j.slasd.2022.03.005
pmc: PMC9670014
mid: NIHMS1844169
pii:
doi:
Substances chimiques
Ligands
0
Nr2f6 protein, mouse
0
Orphan Nuclear Receptors
0
Repressor Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
242-248Subventions
Organisme : NCI NIH HHS
ID : R01 CA225890
Pays : United States
Organisme : NIH HHS
ID : S10 OD025279
Pays : United States
Organisme : NIH HHS
ID : S10 OD026857
Pays : United States
Organisme : NIH HHS
ID : S10 OD030330
Pays : United States
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Cells. 2019 Dec 31;9(1):
pubmed: 31906104
J Exp Med. 2022 Jan 3;219(1):
pubmed: 34812843
Drug Discov Today. 2003 Dec 15;8(24):1128-37
pubmed: 14678739
Nucleic Acids Res. 2013 Nov;41(21):9663-79
pubmed: 23975195
Cell. 1995 Dec 15;83(6):841-50
pubmed: 8521508
Drug Discov Today. 2003 Oct 1;8(19):876-7
pubmed: 14554012
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Endocr Rev. 1999 Oct;20(5):689-725
pubmed: 10529899
Science. 1999 Apr 30;284(5415):757-60
pubmed: 10221899
J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
Genome Res. 2009 Dec;19(12):2324-33
pubmed: 19767417
J Med Chem. 2010 Apr 8;53(7):2719-40
pubmed: 20131845
Immunity. 2008 Aug 15;29(2):205-16
pubmed: 18701084
Nat Immunol. 2008 Nov;9(11):1297-306
pubmed: 18849990
SLAS Discov. 2020 Dec;25(10):1152-1161
pubmed: 33043784
Trends Immunol. 2016 Jun;37(6):354-363
pubmed: 27105824
Brain Res. 2019 Feb 15;1705:75-94
pubmed: 29709504
Mol Endocrinol. 1992 Sep;6(9):1359-61
pubmed: 1331771
J Biomol Screen. 2013 Sep;18(8):930-7
pubmed: 23640875
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
J Med Chem. 2009 Nov 12;52(21):6752-6
pubmed: 19827778
J Am Chem Soc. 2002 Feb 27;124(8):1594-6
pubmed: 11853431
Sci Adv. 2020 Apr 29;6(18):eaaz8031
pubmed: 32494682
J Autoimmun. 2012 Dec;39(4):428-40
pubmed: 22921335
Cell Rep. 2015 Sep 29;12(12):2072-85
pubmed: 26387951
Biomed Res Int. 2015;2015:314620
pubmed: 26583099
ACS Pharmacol Transl Sci. 2018 Sep 14;1(2):134-137
pubmed: 32219209
SLAS Discov. 2019 Mar;24(3):386-397
pubmed: 30682260
Cell Commun Signal. 2014 Jun 12;12:38
pubmed: 24919548
Cell Metab. 2014 Feb 4;19(2):193-208
pubmed: 24440037
Nat Rev Clin Oncol. 2014 Feb;11(2):91-9
pubmed: 24445516